Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.45 USD
+0.12 (9.02%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.43 -0.02 (-1.38%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.45 USD
+0.12 (9.02%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.43 -0.02 (-1.38%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Zacks News
Certara, Inc. (CERT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Certara, Inc. (CERT) delivered earnings and revenue surprises of -88.89% and 8.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 11.11% and -7.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Clearside Biomedical, Inc. (CLSD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 8.33% and 5.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Clearside Biomedical, Inc. (CLSD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Clearside Biomedical (CLSD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.
Analysts Estimate Clearside Biomedical, Inc. (CLSD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.69% and -98.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) NGS-Based Platform Approved for Use in Russia
by Zacks Equity Research
Illumina and R-Pharm's in-vitro diagnostics platform registration will drive the expansion of Next Generation Sequencing-based clinical diagnostics across Russia.
QIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing
by Zacks Equity Research
QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.
Earnings Preview: Clearside Biomedical, Inc. (CLSD) Q4 Earnings Expected to Decline
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN (QGEN) Launches QIAcube Connect MDx Platform Globally
by Zacks Equity Research
QIAGEN's (QGEN) QIAcube Connect MDx platform can be used with more than 140 standard protocols and it ensures complete consistency of the purification of multiple sample types.
Medtronic's (MDT) HVAD Pump Kit Recall Classified as Class I
by Zacks Equity Research
The latest back-to-back incidents will, undoubtedly, create a major drag in Medtronic's (MDT) VAD performance.
Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss
by Zacks Equity Research
Bayer (BAYRY) reports in-line earnings and misses sales estimates in the fourth quarter of 2020.
Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat
by Zacks Equity Research
Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.
bluebird (BLUE) Q4 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss but misses sales estimates in the fourth quarter of 2020.
Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial Cancer
by Zacks Equity Research
Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.
bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies
by Zacks Equity Research
bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.
What's in the Cards for Arcturus (ARCT) This Earnings Season?
by Zacks Equity Research
Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.
Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats both earnings and sales estimates in the fourth quarter of 2020.
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.
Clearside Biomedical's (CLSD) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Clearside Biomedical (CLSD).
AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study
by Zacks Equity Research
AzurRX (AZRX) is developing its pipeline candidate, MS1819, as monotherapy as well in combination with standard of care for treating exocrine pancreatic insufficiency in patients with cystic fibrosis.
Implied Volatility Surging for Clearside Biomedical (CLSD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.